How India Exports Citalopram to the World

In the United States, citalopram is approved for the treatment of depression. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for citalopram, indicating a competitive generic market. Notably, the FDA issued a safety communication in August 2011, highlighting that doses above 40 mg per day can cause abnormal heart rhythms, leading to a revision of dosing recommendations. As of March 2026, there are no active FDA import alerts specifically targeting citalopram from Indian manufacturers, suggesting compliance with U.S. regulatory standards.

In the European Union, citalopram is authorized for marketing under the centralized procedure managed by the European Medicines Agency (EMA). The UK's Medicines and Healthcare products Regulatory Agency (MHRA) also oversees citalopram's approval and monitoring. Manufacturers exporting to these regions must adhere to Good Manufacturing Practice (GMP) standards as outlined in EU Directive 2003/94/EC. Compliance with these standards is essential for maintaining market authorization and ensuring product quality and safety.

Citalopram is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, citalopram is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, citalopram is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international trade regulations.

The primary patents for citalopram have expired, leading to a robust generic market. This expiration has facilitated the entry of multiple generic manufacturers, intensifying competition and contributing to the drug's affordability and widespread availability.

In June 2025, the NPPA conducted a review of antidepressant pricing, including citalopram, to assess market dynamics and ensure fair pricing practices. In September 2025, the CDSCO issued updated guidelines for the export of pharmaceutical products, emphasizing stringent quality control measures to align with international standards. In December 2025, the WHO updated its Essential Medicines List, reaffirming the inclusion of citalopram, highlighting its continued relevance in global mental health treatment protocols.

These developments reflect the dynamic regulatory landscape governing citalopram, emphasizing the importance of compliance with international standards to maintain market access and ensure patient safety.

Citalopram, a widely prescribed antidepressant, relies on Active Pharmaceutical Ingredients (APIs) that are predominantly manufactured in India. However, the production of these APIs is heavily dependent on Key Starting Materials (KSMs) and intermediates imported from China. This dependency poses a significant risk, as any disruption in the supply chain from China can directly impact the availability of citalopram. For instance, in November 2025, geopolitical tensions led to temporary export restrictions from China, causing delays in the supply of critical KSMs to Indian manufacturers.

Recognizing this vulnerability, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to bolster domestic production of 41 critical KSMs, DIs, and APIs. As of September 2025, this initiative has resulted in the establishment of manufacturing capacities for 26 KSMs and APIs, leading to cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. Despite these efforts, the transition to self-reliance is ongoing, and the industry remains susceptible to external supply chain disruptions.

Our proprietary trade data indicates that the top five exporters of citalopram from India account for 65.8% of the total export value, with MEDISPRAY LABORATORIES PRIVATE LIMITED alone contributing 30.5%. This high supplier concentration introduces a single-source risk, where operational or financial issues within these key companies could significantly disrupt the global supply of citalopram.

To mitigate such risks, the PLI Scheme for Pharmaceuticals has been expanded to encourage broader participation among manufacturers. By September 2025, the scheme had attracted a cumulative investment of ₹40,890 crore, surpassing the initial commitment of ₹17,275 crore. This substantial investment aims to diversify the manufacturing base and reduce dependency on a limited number of suppliers.

The global pharmaceutical supply chain is vulnerable to geopolitical tensions and shipping disruptions. Incidents such as the blockade of the Red Sea in January 2026 and heightened tensions in the Strait of Hormuz have led to delays and increased shipping costs for pharmaceutical exports. Additionally, ongoing trade disputes between the United States and China have resulted in regulatory uncertainties, affecting the import of essential raw materials.

These disruptions have prompted regulatory bodies like the FDA and EMA to issue shortage alerts for various medications, including citalopram, in February 2026. Such alerts underscore the need for a resilient supply chain capable of withstanding geopolitical and logistical challenges.

• Diversify Supplier Base: Encourage the development of multiple suppliers for citalopram APIs and KSMs to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Accelerate the implementation of the PLI Scheme to boost domestic manufacturing of critical KSMs and APIs, thereby reducing reliance on imports.

• Strengthen Supply Chain Monitoring: Implement robust monitoring systems to detect early signs of supply chain disruptions and enable proactive responses.

• Develop Strategic Reserves: Establish reserves of essential raw materials and finished products to buffer against short-term supply interruptions.

• Foster International Collaboration: Engage in international partnerships to share best practices and coordinate responses to global supply chain challenges.

RISK_LEVEL: MEDIUM